

1 **Multiomic Mendelian randomization-based insights**
2 **into the role of neutrophil extracellular trap-related**
3 **genes in sepsis**

4
5 Yanbo Liu^{1,¶,*}, Yuhui Li^{2,¶}, Jinmin Chen¹, Yongxia Cai¹, Lukai Lv³

6 ¹Department of Emergency, Sir Run Run Shaw Hospital, Zhejiang University School of
7 Medicine, Hangzhou, Zhejiang Province, China.

8 ²Department of Ultrasonography Lab, Women's Hospital, Zhejiang University School of
9 Medicine, Hangzhou, Zhejiang Province, China.

10 ³Department of Emergency, Wuyi County People's Hospital, Jinhua, Zhejiang Province,
11 China.

12

13 **¶Equal contribution**

14 ***Corresponding author:**

15 Yanbo Liu

16 Email: 1282686740@qq.com

17

18 **Short title:** MR analysis of NET-related genes in sepsis

19

20

21

22 **Abstract**

23 Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to
24 infection. Neutrophil extracellular traps (NETs) have been implicated in the pathogenesis of
25 sepsis, yet the precise role of NET-related genes (NRGs) remains unclear. This study
26 employed a multiomic Mendelian randomization (MR) approach, leveraging genetic variants
27 as instrumental variables to investigate the relationships between NRGs and sepsis risk. We
28 systematically identified 69 NRGs based on literature and database reviews. Utilizing the IEU
29 OpenGWAS Project database, we extracted genetic data for sepsis cases and controls.
30 Expression quantitative trait loci, methylation quantitative trait loci (mQTLs), and protein
31 quantitative trait loci (pQTLs) associated with NRGs were obtained from the eQTLGen
32 Consortium, mQTL meta-analysis, and deCODE Genetics datasets, respectively. We
33 employed the inverse variance-weighted method, supplemented by MR-Egger regression,
34 weighted median, and Bayesian colocalization analysis, and identified four genes (*CXCR1*,
35 *CXCR2*, *ENTPD4*, and *MAPK3*) significantly associated with sepsis risk. Three CpG sites
36 associated with these genes were identified through mQTL-based MR analysis. Additionally,
37 ten proteins showed significant associations with sepsis risk in pQTL-based MR analysis.
38 Summary-data-based MR and colocalization analyses confirmed the causal relationship
39 between *CXCR2* and sepsis, which remained unaffected by pleiotropy. The DNA methylation
40 level at cg06547715, located in the *CXCR2* enhancer region, was inversely correlated with
41 *CXCR2* expression and sepsis risk. These findings suggest that NRGs, particularly *CXCR2*,
42 play a crucial role in sepsis susceptibility and that the DNA methylation status of *CXCR2* may
43 modulate gene expression, influencing sepsis risk. This study provides novel insights into the

44 molecular epidemiology of sepsis and highlights the potential of NRGs as therapeutic targets.

45 Targeting *CXCR2* and its regulatory mechanisms may offer a new avenue for sepsis

46 management. These findings contribute to the theoretical understanding of sepsis

47 pathogenesis and pave the way for future research into precision medicine for sepsis.

48

49 **Keywords:** Sepsis, Neutrophil Extracellular Traps, Mendelian Randomization, Multiomics,

50 *CXCR2*, DNA Methylation

51 **Introduction**

52 Sepsis, an abnormal response to infection, is a leading cause of death among critically ill
53 patients worldwide[1, 2]. Marked by systemic inflammation, it can quickly lead to organ
54 failure and death in the absence of prompt treatment[3, 4]. The pathophysiology of sepsis is
55 complex, involving an intricate interplay among the host immune system, coagulation
56 cascade, and endothelium[5, 6]. Despite advances in critical care and antibiotic therapy,
57 sepsis management continues to pose a significant challenge, highlighting the need for
58 attaining a deeper understanding of the mechanisms underlying this condition and for the
59 development of novel therapeutic strategies[7-9].

60 Recent studies have highlighted the role of neutrophil extracellular traps (NETs) in the
61 pathogenesis of sepsis, particularly in the context of COVID-19 infections, wherein NETs
62 have been implicated in the hyperinflammatory response and microthrombi formation[10,
63 11]. Neutrophils, the most abundant leukocytes in the human body, play a pivotal role in the
64 innate immune response against infections[12, 13]. Among their various defense mechanisms,
65 the formation of NETs has emerged as a critical process in pathogen clearance[14]. NETs are
66 web-like structures composed of DNA, histones, and antimicrobial proteins, which are
67 released by neutrophils through a process termed NETosis[15, 16]. While NETs are effective
68 in trapping and neutralizing a broad spectrum of microbes, excessive NET formation has been
69 implicated in the pathogenesis of various inflammatory and thrombotic conditions, including
70 sepsis[17, 18]. The recognition of NETs in the context of sepsis has led to a paradigm shift in
71 understanding the role of neutrophils in disease pathogenesis. NETs have been shown to
72 contribute to the formation of microthrombi, exacerbating tissue injury and organ dysfunction

73 during sepsis[19, 20]. Furthermore, NETs can serve as a source of proinflammatory
74 mediators, potentially driving the systemic inflammation observed in sepsis[21, 22].

75 The involvement of NETs in sepsis is increasingly being recognized, but the mechanisms
76 governing their formation and their impact on disease severity remain poorly understood[23].
77 Given the potential impact of NETs on sepsis outcomes, elucidating the genetic and
78 molecular factors that regulate NETosis is an urgent need. Identifying key regulators of NET
79 formation may reveal novel therapeutic targets for mitigating the detrimental effects of
80 excessive NET production in sepsis. In this study, we employed two-sample Mendelian
81 randomization (MR), a powerful epidemiological tool that leverages genetic variants as
82 instrumental variables (IVs)[24]. Through the analysis of large-scale genome-wide
83 association studies (GWASs) and quantitative trait loci (QTL), we investigated the causal
84 relationship between NETosis-related genes (NRGs) and sepsis risk.

85

86 **Materials and methods**

87 **Data acquisition**

88 **Identification of NRGs**

89 We systematically identified and curated a comprehensive list of 69 NRGs based on a
90 thorough review of the existing literature and databases[14, 25], focusing on the role of NETs
91 in immunity and various diseases. The selection criteria for these genes included their
92 involvement in the formation, regulation, and biological impact of NETs, encompassing
93 ligands and receptors that stimulate NETs, downstream signaling pathways, and molecules
94 known to be components of the NET framework (**S1 Table**).

95 **Data sources of methylation, expression, and protein QTLs**

96 We accessed publicly available genomic data relevant to sepsis using the "IEU
97 OpenGWAS Project" database. This database, known for its extensive collection of GWAS
98 data, provided a robust platform for our investigation. Specifically, we extracted data from the
99 hospital episode statistics, which included two sepsis datasets—a primary dataset
100 (ieu-b-4980) consisting of 11,643 sepsis cases and 474,841 control participants, and a
101 validation dataset (ieu-b-5088) comprising 11,568 sepsis cases and 451,301 control subjects
102 (**S2 Table**). Both datasets included individuals of European ancestry, ensuring genetic
103 homogeneity was maintained for the MR analyses. To screen for expression quantitative trait
104 locus (eQTL) IVs of the NRGs, genetic variants robustly associated with gene expression
105 within a 1000 kb range on either side of the coding sequence (cis) were extracted from the
106 eQTL summary statistics obtained from the eQTLGen Consortium
107 (<https://www.eqtlgen.org/cis-eqtls.html>). The eQTLGen Consortium includes information on
108 10,317 single nucleotide polymorphisms (SNPs) associated with traits from 31,684
109 individuals. Using the methylation quantitative trait locus (mQTL) data from a meta-analysis
110 of summary statistics from two cohorts (n = 1980) available at
111 (https://yanglab.westlake.edu.cn/data/SMR/LBC_BSGS_meta_lite.tar.gz), cis-mQTL IVs
112 robustly associated with NRG methylation were extracted. From the deCODE Genetics
113 dataset of 4907 proteins (<https://www.decode.com/summarydata/>), cis-protein quantitative
114 trait locus (pQTL) IVs associated with the expression of proteins related to NRGs were
115 selected; all SNPs included in the initial analysis met the criterion of $P < 5 \times 10^{-8}$.

116 **MR analysis**

117 **Assumptions and approach**

118 We used two-sample MR to examine the causal relationships between the QTLs of 69
119 NRGs and sepsis development. The two-sample MR technique utilizes genetic variants as IVs
120 to estimate the causal effects of modifiable risk factors by leveraging the random assortment
121 of alleles at conception. The application of MR in this study was based on three key
122 assumptions—(1) IVs are strongly associated with the exposure of interest; (2) IVs are
123 independent of confounders that could influence the outcome; (3) IVs affect the outcome
124 solely through exposure. Deviations from these assumptions, particularly through pleiotropy,
125 where IVs affect the outcome through multiple biological pathways, can bias MR estimates.

126 **IV selection**

127 The selection of IVs for each NRG was based on established criteria. eQTLs, mQTLs,
128 and pQTLs associated with NRGs were considered as potential IVs. The criteria for IV
129 selection included the following: (1) a genome-wide significant association between the SNP
130 and the gene ($P < 5 \times 10^{-8}$); (2) minimal linkage disequilibrium among SNPs ($r^2 < 0.1$) with a
131 threshold distance of 10,000 kb to ensure independence; (3) exclusion of SNPs with
132 palindromic sequences to harmonize exposure and outcome datasets, followed by
133 MR-PRESSO testing to exclude outlier SNPs; (4) an F-statistic ≥ 10 [F-statistic =
134 $(\text{beta}/\text{se})^2$][26] to ensure sufficient statistical power for the IVs in the analysis.

135 **Two-sample MR analysis and assessment of heterogeneity and pleiotropy**

136 The primary two-sample MR analysis was conducted using the inverse
137 variance-weighted (IVW) method. Before IVW analysis, the datasets were assessed for
138 heterogeneity using Cochran's Q test with a significance threshold of $P < 0.05$. A

139 random-effects IVW model was used in the presence of significant heterogeneity, while a
140 fixed-effects IVW model was applied when no heterogeneity was detected. Complementary
141 MR methods were employed to strengthen the findings, including MR-Egger regression,
142 weighted median, weighted model, and simple model. The *P*-values were adjusted to control
143 the false discovery rate (FDR) at $\alpha = 0.05$ using the Benjamini-Hochberg method. The
144 estimated causal effects were quantified using the odds ratio (OR) and the 95% confidence
145 interval (CI). The MR-Egger regression intercept test was used to assess potential pleiotropy,
146 with a non-significant $P > 0.05$ indicating the absence of horizontal pleiotropy. Cochran's Q
147 statistic from both the MR-Egger and IVW methods was used to detect heterogeneity among
148 various causal effects, with a Cochran's Q test $P < 0.05$ indicating heterogeneity[26, 27]. We
149 also employed the Steiger filtering method to verify the directional associations among
150 eQTLs, mQTLs, and sepsis.

151 **Summary-data-based MR (SMR)**

152 **SMR analysis and heterogeneity in the dependent instrument (HEIDI) testing**

153 SMR was employed to ascertain the causal inferences of NRG methylation, expression,
154 and protein abundance with the risk of sepsis, based on the top associated cis-QTLs. SMR can
155 reach a much higher statistical power than conventional MR analysis when exposure and
156 outcome are available from two independent samples with large sample sizes. The top
157 associated cis-QTLs were selected by considering a window centered around the
158 corresponding gene (± 1000 kb) and passing a *P*-value threshold of 5.0×10^{-8} . The SNPs with
159 allele frequency differences larger than the specified threshold (set as 0.2 in the present study)
160 between any pairwise datasets, including the linkage disequilibrium reference sample, the

161 QTL summary data, and the outcome summary data, were excluded. The HEIDI test was
162 applied to distinguish pleiotropy from linkage, where P-HEIDI values <0.01 were considered
163 to be likely due to pleiotropy and thus discarded from the analysis. SMR and HEIDI tests
164 were implemented using the SMR software (version 1.3.1).

165 **Colocalization analysis**

166 To confirm the results, we used the coloc R package (version 5.2.3, available at
167 <https://chr1swallace.github.io/coloc/>)[28] for Bayesian collocation analysis to estimate the
168 posterior probabilities of shared variants. The collocation analysis relies on four
169 hypotheses—(1) Phenotype 1 (GWAS) and Phenotype 2 (e.g., eQTL) show no significant
170 SNP associations in a specific genomic region (H0); (2) Phenotype 1 (GWAS) or Phenotype 2
171 (e.g., eQTL) shows a significant association with SNPs in a specific genomic region (H1/H2);
172 (3) Phenotype 1 (GWAS) and Phenotype 2 (e.g., eQTL) are significantly associated with
173 SNPs in a specific genomic region, but driven by different causal variants (H3); (4)
174 Phenotype 1 (GWAS) and Phenotype 2 (e.g., eQTL) are significantly associated with SNPs in
175 a specific genomic region and driven by the same causal variant (H4). We extracted all SNPs
176 within 100 kb upstream and downstream of the lead SNP in the GWAS for collocation
177 analysis and calculated the posterior probability H4 (PPH4). In academic contexts, a PPH4
178 value exceeding 0.75 is conventionally employed as the threshold to indicate evidence of
179 collocation between GWAS and QTL associations.

180 **Ethical Considerations**

181 The data sources utilized in this study, including the IEU OpenGWAS Project, eQTLgen,
182 the mQTL summary data of McRae et al., and the deCODE Genetics dataset, are all publicly

183 accessible and do not contain any personal identifiers or sensitive personal information that
184 would require consent. The study followed the Declaration of Helsinki principles and human
185 subject research guidelines.

186 **Results**

187 **Analytical process overview**

188 In this study, two-sample MR analysis of IVs was performed separately for sepsis at the
189 levels of gene expression, methylation, and protein abundance to identify candidate genes
190 associated with sepsis. These genes were validated using SMR analysis, and significant
191 eQTLs and mQTLs were advanced to an integrated analysis followed by validation in an
192 independent cohort. This rigorous process culminated in the identification of *CXCR2* as a
193 notably associated gene (**Fig 1**).

194

195 **Fig 1. Overview of the study design.**

196

197 **eQTL-based MR analysis**

198 By intersecting our NRGs with key cis-eQTLs from the eQTLGen consortium, we
199 identified 62 genes that met our criteria. Applying the established criteria for selecting IVs,
200 we identified 438 cis-eQTLs associated with these 62 NRGs as the final IVs within our
201 exposure data. A two-sample MR analysis of patients with sepsis was performed. Using the
202 IVW method as our primary analytical approach, we identified four genes significantly
203 associated with sepsis risk (FDR<0.05) (**S3 Table, Fig 2**). These genes include *CXCR1* (OR:
204 1.11, 95% CI: 1.04–1.17; FDR = 2.21×10^{-2}), *CXCR2* (OR: 1.14, 95% CI: 1.07–1.21; FDR =

205 2.68×10^{-3}), *ENTPD4* (OR: 1.16, 95% CI: 1.09–1.24; FDR = 2.49×10^{-4}), and *MAPK3* (OR:
206 0.96, 95% CI: 0.93–0.99; FDR = 4.59×10^{-2}). The primary analysis demonstrated the absence
207 of heterogeneity ($P > 0.05$, **S4 Table**) and pleiotropy ($P > 0.05$, **S5 Table**). Additionally,
208 Steiger filtering corroborated the directional relationship between outcomes and exposures
209 (**S6 Table**).

210

211 **Fig 2. Mendelian randomization results for the association between the expression of**
212 **neutrophil extracellular trap-related genes and sepsis risk.**

213

214 **mQTL-based MR analysis**

215 To further explore the epigenetic mechanisms influencing susceptibility to sepsis, we
216 analyzed mQTLs associated with NRGs. Following stringent criteria for selecting IVs, we
217 identified 780 cis-mQTLs across 55 NRGs that qualified as the final IVs within our exposure
218 dataset. We then performed two-sample MR analysis of patients with sepsis. Using the IVW
219 method as our primary analytical approach, we identified three CpG sites significantly
220 associated with the sepsis risk (FDR<0.05) (**S7 Table, Fig 3**). These sites include
221 cg06547715 (OR: 0.92, 95% CI: 0.88–0.97; FDR = 2.06×10^{-2}), cg14150666 (OR: 0.95, 95%
222 CI: 0.93–0.97; FDR = 3.46×10^{-3}), and cg24126361 (OR: 0.97, 95% CI: 0.95–0.99; FDR =
223 2.06×10^{-2}), associated with the genes *CXCR2* and *CXCR1*, respectively. The primary
224 analysis did not indicate any evidence of heterogeneity ($P > 0.05$, **S8 Table**) or pleiotropy
225 ($P > 0.05$, **S9 Table**).

226

227 **Fig 3. Mendelian randomization results for the association between neutrophil**
228 **extracellular trap-related gene methylation and sepsis risk.**

229

230 **pQTL-based MR analysis**

231 By screening cis-pQTL data associated with NRGs, we identified 2304 SNPs across 36
232 NRGs in the exposure data as the final IVs based on the selection criteria ($FDR < 0.05$). Ten
233 proteins were independently associated with sepsis risk. *SIGLEC14* (OR: 1.02, 95% CI:
234 1.01–1.04; $FDR = 8.05 \times 10^{-3}$) and *SIGLEC5* (OR: 1.02, 95% CI: 1.01–1.04; $FDR = 1.13 \times$
235 10^{-2}) were positively associated with sepsis risk. Conversely, *AKT2* (OR: 0.94, 95% CI:
236 0.90–0.97; $FDR = 4.41 \times 10^{-3}$), *CEACAM3* (OR: 0.75, 95% CI: 0.66–0.85; $FDR = 7.57 \times$
237 10^{-5}), *CTSG* (OR: 0.80, 95% CI: 0.69–0.92; $FDR = 8.77 \times 10^{-3}$), *F3* (OR: 0.70, 95% CI:
238 0.61–0.82; $FDR = 7.57 \times 10^{-5}$), *FCAR* (OR: 0.72, 95% CI: 0.56–0.91; $FDR = 2.07 \times 10^{-2}$),
239 *HMGB1* (OR: 0.83, 95% CI: 0.76–0.90; $FDR = 7.57 \times 10^{-5}$), *IL17A* (OR: 0.63, 95% CI:
240 0.44–0.90; $FDR = 3.55 \times 10^{-2}$), and *ITGB2* (OR: 0.77, 95% CI: 0.69–0.88; $FDR = 3.19 \times$
241 10^{-4}), were inversely associated with sepsis risk (**S10 Table, Fig 4**). In the primary analysis,
242 no heterogeneity ($P > 0.05$, **S11 Table**) or horizontal pleiotropy ($P > 0.05$, **S12 Table**) was
243 observed.

244

245 **Fig 4. Mendelian randomization results for the association between neutrophil**
246 **extracellular trap-related proteins and sepsis risk.**

247

248 **SMR and colocalization analyses**

249 Further SMR analysis was conducted to verify the causal relationships between mQTLs
250 and sepsis, eQTLs and sepsis, as well as pQTLs and sepsis. The protein data were not
251 significant after SMR analysis, and the *CXCR2* gene was identified through mQTL and eQTL
252 SMR analyses. The results indicated that *CXCR2* was consistent with the direction of the
253 effect observed in the MR analysis and passed the HEIDI ($P > 0.01$) and SMR tests ($P <$
254 0.05), suggesting a causal relationship unconfounded by pleiotropy. The SMR plots and effect
255 estimates are presented in the **S13 Table** and **Fig 5A, B**. Other genes did not demonstrate
256 significant associations in these analyses. Upon further exploring the causal relationships
257 between these genes and sepsis, colocalization analysis revealed the details of SNPs (**Fig 5B**)
258 and showed that *CXCR2* (OR: 1.16, 95% CI: 1.05–1.29; PPH4 = 1), cg06547715 (OR: 0.92,
259 95% CI: 0.87–0.97; PPH4 = 0.912), and cg14150666 (OR: 0.96, 95% CI: 0.93–0.99; PPH4 =
260 1) shared a causal variant with sepsis, which added another evidence to our results (**S14-S16**
261 **Tables, Fig 5C**).

262

263 **Fig 5. SMR and colocalization analysis results in discovery datasets (ieu-b-4980 cohort).**

264 A. MR association between *CXCR2* expression and sepsis risk. B. MR association between
265 *CXCR2* methylation and sepsis risk. C. Colocalization evidence of the expression and CpG
266 site methylation of *CXCR2* and sepsis susceptibility.

267

268 **Integration of GWAS and *CXCR2*-related eQTL/mQTL data from**
269 **the blood**

270 Subsequently, we hypothesized that gene expression could be the underlying mechanism
271 explaining the plausible causality in the disease. Moreover, DNA methylation (DNAm) in
272 promoters or enhancers typically plays a crucial role in the regulation of disease-associated
273 target genes. In this study, we identified *CXCR2*, which encodes a protein belonging to the G
274 protein-coupled receptor family. This protein serves as a receptor for interleukin 8, which
275 binds with high affinity and transmits signals through the G-protein-activated second
276 messenger system. Additionally, this receptor can bind to chemokine (C-X-C motif) ligand 1
277 (*CXCL1/MGSA*), which is known to stimulate melanoma growth. This receptor mediates the
278 migration of neutrophils to sites of inflammation. After three-step SMR analysis, we
279 discovered that the DNAm probe cg06547715 located in the enhancer region of *CXCR2* plays
280 a crucial role in gene expression regulation. Methylation levels at this site negatively correlate
281 with *CXCR2* expression ($\beta\text{SMR} = -0.658$) and sepsis ($\beta\text{SMR} = -0.082$). Conversely, the
282 expression levels of *CXCR2* are positively correlated with sepsis ($\beta\text{SMR} = 0.13$). This
283 suggests that reduced DNAm levels within the enhancer region of *CXCR2* may upregulate its
284 expression, increasing susceptibility to sepsis (**S17 Table**).

285 **Replication of results in other cohorts**

286 We performed SMR analysis of *CXCR2* in the ieu-b-5088 cohort to validate our findings.
287 The results showed the methylation level at the cg06547715 site negatively correlated with
288 sepsis ($\beta\text{SMR} = -0.0604334$), and *CXCR2* expression levels were positively correlated with
289 the condition ($\beta\text{SMR} = 0.114256$), aligning with the effects observed in cohort ieu-b-4980
290 (**S18 Table; Fig 6A, B**). Colocalization analysis depicted the details of SNPs locus (**Fig 5B**)
291 and showed that *CXCR2* (OR: 1.12, 95% CI: 1.01–1.24; PPH4=1), cg06547715 (OR: 0.94,

292 95% CI: 0.89–0.99; PPH4=0.912), and cg14150666 (OR 0.97, 95% CI 0.94–1.00; PPH4=1)

293 shared a causal variant with sepsis, which added additional evidence to our results (**S19-S21**

294 **Tables; Fig 6C**).

295

296 **Fig 6. SMR and colocalization analysis results in validation datasets (ieu-b-5088 cohort).**

297 A. MR association between *CXCR2* expression and sepsis risk. B. MR association between

298 *CXCR2* methylation and sepsis risk. C. Colocalization evidence of the expression and CpG

299 site methylation of *CXCR2* and susceptibility to sepsis.

300

301 **Discussion**

302 This study leveraged the multiomic MR method to explore the relationship of NRGs

303 with sepsis risk. Our findings not only contribute to the existing literature but also provide a

304 foundation for future therapeutic interventions. The identification of *CXCR1*, *CXCR2*,

305 *ENTPD4*, and *MAPK3* as genes significantly associated with sepsis risk is consistent with the

306 growing body of evidence suggesting that chemokine signaling and immune response genes

307 are critical in sepsis pathogenesis. The involvement of *CXCR1* underscores the critical role of

308 neutrophil chemotaxis in sepsis. Our findings are consistent with those of previous studies,

309 suggesting that polymorphisms in these genes modulate the immune response to infection[29,

310 30]. The association between *ENTPD4* and sepsis risk is intriguing, given its role in

311 purinergic signaling, which has been implicated in the regulation of NET formation[31, 32].

312 Similarly, the observed association with *MAPK3*, a key regulator of cellular stress responses,

313 aligns with the hypothesis that NETs are part of a broader inflammatory network during
314 sepsis[33, 34]. The robust association of *CXCR2*, in particular, resonates with prior research
315 indicating its role in modulating neutrophil migration and the inflammatory cascade central to
316 sepsis[35-37]. Our multiomic MR approach, which integrates genetic, epigenetic, and
317 proteomic data, strengthens the causal inference by mitigating confounding and reverse
318 causation biases inherent in observational studies. The results of colocalization analysis
319 provided us with additional evidence supporting the role of the *CXCR2* gene in sepsis. Our
320 analysis showed that the gene expression of *CXCR2* is significantly associated with the risk of
321 sepsis development, and the PPH4 value is greater than 0.75, indicating that the association
322 between GWAS and eQTL may be caused by the same causal variant. This finding further
323 strengthens the possibility of using *CXCR2* as a potential therapeutic target for sepsis.

324 The inverse correlation between DNAm at cg06547715 and *CXCR2* expression and its
325 subsequent impact on sepsis risk offer a novel perspective on the epigenetic modulation of
326 immune response genes[38, 39]. This aligns with the emerging paradigm that epigenetic
327 modifications, especially DNAm, are dynamic and responsive to environmental stimuli,
328 potentially serving as a molecular switch in the context of sepsis[40]. The implications of our
329 findings extend to the realm of therapeutics, where targeting *CXCR2* and its regulatory
330 mechanisms could represent a new frontier in sepsis management[30]. The potential to
331 modulate gene expression through epigenetic drugs or gene therapies offers a promising
332 avenue for mitigating the hyperinflammatory state characteristic of sepsis. Furthermore, the
333 pQTL analysis revealed a direct link between specific proteins and the risk of sepsis
334 development. By screening cis-pQTL data associated with NRGs, we identified 10 proteins

335 that are significantly associated with the risk of sepsis. For instance, *SIGLEC14* and *SIGLEC5*
336 are positively correlated, whereas *AKT2*, *CEACAM3*, *CTSG*, *F3*, *FCAR*, *HMGB1*, *IL17A*, and
337 *ITGB2* are negatively correlated with the risk of sepsis development. These findings suggest
338 that these proteins may play a key role in the pathogenesis of sepsis, offering new leads for
339 the development of targeted therapeutic strategies in the future[41-46]. Our results are in line
340 with those of previous studies that have implicated NRGs in various inflammatory and
341 autoimmune conditions, suggesting a common pathway in the dysregulation of immune
342 responses[47, 48]. The consistency of our findings with those from independent cohorts and
343 the replication of results across different analytical approaches lend credence to the
344 robustness of our conclusions. While our multiomic MR approach provides a robust platform
345 for causal inference, it is not without limitations. The reliance on observational data exposes
346 our study to potential unmeasured confounding despite the use of MR methods to control for
347 such biases. Due to the limited number of NRG proteins in the pQTL dataset, the present
348 study did not fully explore the causal relationship between mitochondrial proteins and the risk
349 of sepsis development.

350 Future research should aim to replicate our findings in diverse populations and
351 investigate the functional consequences of the genetic and epigenetic variants identified.
352 Additionally, experimental studies are warranted to elucidate the mechanistic links among
353 NRGs, inflammation, and sepsis development, potentially leading to the discovery of new
354 biomarkers and therapeutic targets.

355 In conclusion, our multiomic MR study provides a deeper understanding of the role of
356 NRGs in sepsis, with a particular focus on *CXCR2*. Our findings have significant implications

357 for the development of precision medicine strategies for sepsis and highlight the importance
358 of integrating genetic and epigenetic data in the quest for novel therapeutic targets. The
359 identification of *CXCR2* as a key gene in sepsis risk offers a promising starting point for
360 future research and interventional studies aimed at improving the outcomes in patients with
361 this devastating condition.

362

363 **Acknowledgments**

364 We gratefully acknowledge the authors and participants of all GWASs, including the IEU
365 OpenGWAS Project, eQTLgen, the mQTL summary data of McRae et al., and the deCODE
366 Genetics dataset, from which we utilized summary statistics data.

367 **References**

368

- 369 1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al.
370 The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *Jama*.
371 2016;315(8):801-10.
- 372 2. Schlapbach LJ, Watson RS, Sorce LR, Argent AC, Menon K, Hall MW, et al.
373 International Consensus Criteria for Pediatric Sepsis and Septic Shock. *Jama*.
374 2024;331(8):665-74.
- 375 3. De Backer D, Deutschman CS, Hellman J, Myatra SN, Ostermann M, Prescott HC, et al.
376 Surviving Sepsis Campaign Research Priorities 2023. *Critical care medicine*.
377 2024;52(2):268-96.
- 378 4. Cecconi M, Evans L, Levy M, Rhodes A. Sepsis and septic shock. *Lancet (London,*
379 *England)*. 2018;392(10141):75-87.
- 380 5. Bode C, Weis S, Sauer A, Wendel-Garcia P, David S. Targeting the host response in


- 381 sepsis: current approaches and future evidence. *Critical care* (London, England).
382 2023;27(1):478.
- 383 6. Zhang H, Wang Y, Qu M, Li W, Wu D, Cata JP, et al. Neutrophil, neutrophil
384 extracellular traps and endothelial cell dysfunction in sepsis. *Clinical and translational*
385 *medicine*. 2023;13(1):e1170.
- 386 7. Hamilton FW, Thomas M, Arnold D, Palmer T, Moran E, Mentzer AJ, et al. Therapeutic
387 potential of IL6R blockade for the treatment of sepsis and sepsis-related death: A Mendelian
388 randomisation study. *PLoS medicine*. 2023;20(1):e1004174.
- 389 8. Boufenzler A, Carrasco K, Jolly L, Brustolin B, Di-Pillo E, Derive M, et al. Potentiation
390 of NETs release is novel characteristic of TREM-1 activation and the pharmacological
391 inhibition of TREM-1 could prevent from the deleterious consequences of NETs release in
392 sepsis. *Cellular & molecular immunology*. 2021;18(2):452-60.
- 393 9. Ou Q, Tan L, Shao Y, Lei F, Huang W, Yang N, et al. Electrostatic Charge-Mediated
394 Apoptotic Vesicle Biodistribution Attenuates Sepsis by Switching Neutrophil NETosis to
395 Apoptosis. *Small* (Weinheim an der Bergstrasse, Germany). 2022;18(20):e2200306.
- 396 10. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a
397 randomised, controlled, open-label, platform trial. *Lancet* (London, England).
398 2021;397(10285):1637-45.
- 399 11. Warner S, Teague HL, Ramos-Benitez MJ, Panicker S, Allen K, Gaihre S, et al. R406
400 reduces lipopolysaccharide-induced neutrophil activation. *Cellular immunology*.
401 2024;403-404:104860.
- 402 12. Grüneboom A, Aust O, Cibir Z, Weber F, Hermann DM, Gunzer M. Imaging innate
403 immunity. *Immunological reviews*. 2022;306(1):293-303.
- 404 13. Ramoni D, Tirandi A, Montecucco F, Liberale L. Sepsis in elderly patients: the role of
405 neutrophils in pathophysiology and therapy. *Internal and emergency medicine*.
406 2024;19(4):901-17.
- 407 14. Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. *Nature*
408 *reviews Immunology*. 2018;18(2):134-47.
- 409 15. Skallberg A, Bunnfors K, Brommesson C, Uvdal K. Neutrophils Activated by
410 Nanoparticles and Formation of Neutrophil Extracellular Traps: Work Function Mapping and

- 411 Element Specific Imaging. *Analytical chemistry*. 2019;91(21):13514-20.
- 412 16. Kolaczowska E, Jenne CN, Surewaard BG, Thanabalasuriar A, Lee WY, Sanz MJ, et al.
413 Molecular mechanisms of NET formation and degradation revealed by intravital imaging in
414 the liver vasculature. *Nature communications*. 2015;6:6673.
- 415 17. Baz AA, Hao H, Lan S, Li Z, Liu S, Chen S, et al. Neutrophil extracellular traps in
416 bacterial infections and evasion strategies. *Frontiers in immunology*. 2024;15:1357967.
- 417 18. Kiwit A, Lu Y, Lenz M, Knopf J, Mohr C, Ledermann Y, et al. The Dual Role of
418 Neutrophil Extracellular Traps (NETs) in Sepsis and Ischemia-Reperfusion Injury:
419 Comparative Analysis across Murine Models. *International journal of molecular sciences*.
420 2024;25(7).
- 421 19. Zhu S, Yu Y, Qu M, Qiu Z, Zhang H, Miao C, et al. Neutrophil extracellular traps
422 contribute to immunothrombosis formation via the STING pathway in sepsis-associated lung
423 injury. *Cell death discovery*. 2023;9(1):315.
- 424 20. Thiam HR, Wong SL, Wagner DD, Waterman CM. Cellular Mechanisms of NETosis.
425 *Annual review of cell and developmental biology*. 2020;36:191-218.
- 426 21. Kumar S, Payal N, Srivastava VK, Kaushik S, Saxena J, Jyoti A. Neutrophil extracellular
427 traps and organ dysfunction in sepsis. *Clinica chimica acta; international journal of clinical*
428 *chemistry*. 2021;523:152-62.
- 429 22. Yao YM, Osuchowski MF, Wang JH, Pan ZK. Editorial: Immune Dysfunction: An
430 Update of New Immune Cell Subsets and Cytokines in Sepsis. *Frontiers in immunology*.
431 2021;12:822068.
- 432 23. Mengozzi L, Barison I, Malý M, Lorenzoni G, Fedrigo M, Castellani C, et al. Neutrophil
433 Extracellular Traps and Thrombolysis Resistance: New Insights for Targeting Therapies.
434 *Stroke*. 2024;55(4):963-71.
- 435 24. Zuber V, Colijn JM, Klaver C, Burgess S. Selecting likely causal risk factors from
436 high-throughput experiments using multivariable Mendelian randomization. *Nature*
437 *communications*. 2020;11(1):29.
- 438 25. Zhang Y, Guo L, Dai Q, Shang B, Xiao T, Di X, et al. A signature for pan-cancer
439 prognosis based on neutrophil extracellular traps. *Journal for immunotherapy of cancer*.
440 2022;10(6).

- 441 26. Papadimitriou N, Dimou N, Tsilidis KK, Banbury B, Martin RM, Lewis SJ, et al.
442 Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation
443 analysis. *Nature communications*. 2020;11(1):597.
- 444 27. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the
445 MR-Egger method. *European journal of epidemiology*. 2017;32(5):377-89.
- 446 28. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al.
447 Bayesian test for colocalisation between pairs of genetic association studies using summary
448 statistics. *PLoS genetics*. 2014;10(5):e1004383.
- 449 29. Zhao H, Li Y, Sun G, Cheng M, Ding X, Wang K. Single-cell transcriptional gene
450 signature analysis identifies IL-17 signaling pathway as the key pathway in sepsis.
451 *Immunobiology*. 2023;228(6):152763.
- 452 30. AlSabani M, Abrams ST, Cheng Z, Morton B, Lane S, Alosaimi S, et al. Reduction of
453 NETosis by targeting CXCR1/2 reduces thrombosis, lung injury, and mortality in
454 experimental human and murine sepsis. *British journal of anaesthesia*. 2022;128(2):283-93.
- 455 31. Avital-Shacham M, Sharf R, Kleinberger T. NTPDASE4 gene products cooperate with
456 the adenovirus E4orf4 protein through PP2A-dependent and -independent mechanisms and
457 contribute to induction of cell death. *Journal of virology*. 2014;88(11):6318-28.
- 458 32. Shaikh S, Basu S, Bag S, Chatterjee A, Datta S, Banerjee D, et al. Uracil as a biomarker
459 for spatial pyrimidine metabolism in the development of gingivobuccal oral squamous cell
460 carcinoma. *Scientific reports*. 2024;14(1):11609.
- 461 33. Li X, Jiang S, Wang B, He S, Guo X, Lin J, et al. Integrated multi-omics analysis and
462 machine learning developed diagnostic markers and prognostic model based on
463 Efferocytosis-associated signatures for septic cardiomyopathy. *Clinical immunology*
464 (Orlando, Fla). 2024;265:110301.
- 465 34. Cao B, Xu Z, Liu C, Hu J, Zhu Z, Li J, et al. Protective effects of notoginsenoside R1 on
466 acute lung injury in rats with sepsis. *Annals of translational medicine*. 2021;9(12):996.
- 467 35. Wu Y, Wang S, Farooq SM, Castelveter MP, Hou Y, Gao JL, et al. A chemokine
468 receptor CXCR2 macromolecular complex regulates neutrophil functions in inflammatory
469 diseases. *The Journal of biological chemistry*. 2012;287(8):5744-55.
- 470 36. Boppana NB, Devarajan A, Gopal K, Barathan M, Bakar SA, Shankar EM, et al.

- 471 Blockade of CXCR2 signalling: a potential therapeutic target for preventing
472 neutrophil-mediated inflammatory diseases. *Experimental biology and medicine* (Maywood,
473 NJ). 2014;239(5):509-18.
- 474 37. Kim SD, Lee HY, Shim JW, Kim HJ, Yoo YH, Park JS, et al. Activation of CXCR2 by
475 extracellular matrix degradation product acetylated Pro-Gly-Pro has therapeutic effects
476 against sepsis. *American journal of respiratory and critical care medicine*.
477 2011;184(2):243-51.
- 478 38. Caldwell BA, Wu Y, Wang J, Li L. Altered DNA methylation underlies monocyte
479 dysregulation and innate exhaustion memory in sepsis. *bioRxiv : the preprint server for*
480 *biology*. 2023.
- 481 39. Binnie A, Walsh CJ, Hu P, Dwivedi DJ, Fox-Robichaud A, Liaw PC, et al. Epigenetic
482 Profiling in Severe Sepsis: A Pilot Study of DNA Methylation Profiles in Critical Illness.
483 *Critical care medicine*. 2020;48(2):142-50.
- 484 40. Martino D, Kresoje N, Amenyogbe N, Ben-Othman R, Cai B, Lo M, et al. DNA
485 Methylation signatures underpinning blood neutrophil to lymphocyte ratio during first week
486 of human life. *Nature communications*. 2024;15(1):8167.
- 487 41. Kim HG, Lee C, Yoon JH, Kim JH, Cho JY. BN82002 alleviated tissue damage of septic
488 mice by reducing inflammatory response through inhibiting AKT2/NF- κ B signaling pathway.
489 *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*. 2022;148:112740.
- 490 42. Liu YC, Yu MM, Chai YF, Shou ST. Sialic Acids in the Immune Response during
491 Sepsis. *Frontiers in immunology*. 2017;8:1601.
- 492 43. Klaile E, Müller MM, Schäfer MR, Clauder AK, Feer S, Heyl KA, et al. Binding of
493 *Candida albicans* to Human CEACAM1 and CEACAM6 Modulates the Inflammatory
494 Response of Intestinal Epithelial Cells. *mBio*. 2017;8(2).
- 495 44. You G, Zhao X, Liu J, Yao K, Yi X, Chen H, et al. Machine learning-based
496 identification of CYBB and FCAR as potential neutrophil extracellular trap-related treatment
497 targets in sepsis. *Frontiers in immunology*. 2023;14:1253833.
- 498 45. Deng M, Tang Y, Li W, Wang X, Zhang R, Zhang X, et al. The Endotoxin Delivery
499 Protein HMGB1 Mediates Caspase-11-Dependent Lethality in Sepsis. *Immunity*.
500 2018;49(4):740-53.e7.

- 501 46. Nakada TA, Russell JA, Boyd JH, Walley KR. IL17A genetic variation is associated
502 with altered susceptibility to Gram-positive infection and mortality of severe sepsis. *Critical*
503 *care* (London, England). 2011;15(5):R254.
- 504 47. Xiang J, Cao J, Wang X, Shao S, Huang J, Zhang L, et al. Neutrophil extracellular traps
505 and neutrophil extracellular traps-related genes are involved in new-onset atrial fibrillation in
506 LPS-induced sepsis. *International immunopharmacology*. 2024;138:112550.
- 507 48. Tang J, Lu H, Xie Z, Jia X, Su T, Lin B. Identification of potential biomarkers for sepsis
508 based on neutrophil extracellular trap-related genes. *Diagnostic microbiology and infectious*
509 *disease*. 2024;110(1):116380.
- 510



medRxiv preprint doi: <https://doi.org/10.1101/2024.12.24.24319599>; this version posted December 27, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Fig 1

medRxiv preprint doi: <https://doi.org/10.1101/2024.12.24.24319599>; this version posted December 27, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




Fig2

Exposure	CpG	MR Method	No.SNPs		OR(95%CI)	P value	FDR
CXCR2	cg06547715	Weighted mode	3		0.92(0.87-0.97)	1.04e-01	8.80e-01
		Weighted median	3		0.92(0.88-0.97)	1.93e-03	8.60e-02
		Simple mode	3		0.93(0.86-1.01)	2.12e-01	9.51e-01
		MR Egger	3		0.93(0.80-1.07)	4.80e-01	9.99e-01
		Inverse variance weighted	3		0.92(0.88-0.97)	6.93e-04	2.06e-02
cg14150666	cg14150666	Weighted mode	9		0.96(0.93-0.99)	2.63e-02	8.80e-01
		Weighted median	9		0.95(0.93-0.98)	1.23e-03	8.60e-02
		Simple mode	9		0.97(0.92-1.02)	2.26e-01	9.51e-01
		MR Egger	9		0.97(0.91-1.03)	3.97e-01	9.99e-01
		Inverse variance weighted	9		0.95(0.93-0.97)	3.89e-05	3.46e-03
SLC25A37	cg24126361	Weighted mode	14		0.99(0.96-1.01)	2.64e-01	8.80e-01
		Weighted median	14		0.97(0.94-0.99)	5.99e-03	1.78e-01
		Simple mode	14		0.95(0.91-0.99)	2.62e-02	9.51e-01
		MR Egger	14		0.98(0.95-1.02)	3.44e-01	9.99e-01
		Inverse variance weighted	14		0.97(0.95-0.99)	5.89e-04	2.06e-02

medRxiv preprint doi: <https://doi.org/10.1101/2024.12.24.24319599>; this version posted December 27, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Protective factor Risk factor

medRxiv preprint doi: <https://doi.org/10.1101/2024.12.24.24319599>; this version posted December 27, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).






Fig 4




C


Gene	Probe ID	OR(95%CI)	P value	p_HEIDI	PPH4
CXCR2	ENSG00000180871	1.16(1.05-1.29)	3.48e-03	8.05e-01	1.000
CXCR2	cg06547715	0.92(0.87-0.97)	4.40e-03	7.43e-01	0.912
CXCR2	cg14150666	0.96(0.93-0.99)	4.08e-03	7.25e-01	1.000

0 1 2
Protective factor Risk factor

Fig 5



medRxiv preprint doi: <https://doi.org/10.1101/2024.12.24.24319599>; this version posted December 27, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



C

Gene	Probe ID	OR(95%CI)	P value	p_HEIDI	PPH4
CXCR2	ENSG00000180871	1.12(1.01-1.24)	2.45e-02	8.86e-01	1.000
CXCR2	cg06547715	0.94(0.89-0.99)	3.19e-02	9.04e-01	0.912
CXCR2	cg14150666	0.97(0.94-1.00)	2.68e-02	8.93e-01	1.000

0 1 2
Protective factor Risk factor

Fig 6